BIOSURGERY MARKET ANALYSIS

Biosurgery Market, By Treatment Type (Hemostatic Agents, Bone-graft Substitutes, Surgical Sealants and Adhesives, Soft-tissue Attachments, Adhesion Barriers, and Staple Line Reinforcement), By Disease Type (Orthopedic Surgery, General Surgery, Neurological Surgery, Cardiovascular Surgery, Gynecological Surgery, and Other Applications), and By Geography (North America, Europe, Asia Pacific, Middle East and Africa, and Latin America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023
Code : CMI5457
Pages :158
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Biosurgery Market: Key Developments

In May 2020, Baxter International Inc. received the U.S. Food and Drug Administration (FDA) approval for Altapore Shape Bioactive Bone Graft, the latest addition to Baxter’s next-generation bone graft substitute product line.

In June 2020, BD completed the acquisition of Straub Medical AG, a privately-held company that develops and sells medical atherectomy and thrombectomy devices.

In September 2019, Integra LifeSciences Holdings acquired Rebound Therapeutics, the developer of single-use medical devices that enable minimally-invasive access by using optics & illumination for visualization, diagnostics, and therapeutic usage in neurosurgery.

In April 2019, Baxter International received its Floseal Hemostatic matrix for use in surgical procedures. The advanced generation Floseal has 20% fewer components and steps of preparation, which makes it easier and faster for use in operating rooms.